Advent Pharmaceuticals was founded in 2001 by former GlaxoSmithKline employees, with extensive experience in respiratory R&D and commercialization.

Advent’s  core expertise centers on the design and development of Dry Powder Inhaler devices, formulation of medicines for optimal performance in our inhalers and global regulatory strategy.

Advents key accomplishments include:

· Advent’s vip– novel, cartridge-based dry powder inhaler

· Advents Universal Dry Powder Inhaler Platform – next-generation DPI devices

These accomplishments are the result of Advent’s strong, in-house technical knowledge and broad-based expertise, generating key intellectual property and know-how.

Advents Research & Development and Pilot Manufacturing facilities are based in Melbourne, Australia and are backed by a supportive investor base and founders, including CM Capital and QIC BioVentures.

Please direct any enquiries to:

Ms Robin Coleman

Head of Business Development

1 Dalmore Drive

Scoresby

Victoria, Australia 3179

Phone: +61 3 9763 9966

E-mail: rcoleman@advent-pharma.com